Weiss Ratings Reiterates "Sell (D-)" Rating for BioLife Solutions (NASDAQ:BLFS)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for BioLife Solutions (NASDAQ: BLFS), which may signal ongoing concerns regarding its stock performance.
• Despite the negative rating from Weiss, other analysts have provided a mix of ratings, with seven analysts recommending a Buy, one a Hold, and another a Sell, suggesting a consensus rating of "Moderate Buy" and an average price target of $31.29.
• BioLife Solutions reported earnings per share of ($0.33) for the latest quarter, which missed estimates by $0.31, although revenue exceeded expectations at $25.42 million.

BioLife Solutions (NASDAQ:BLFS - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

BLFS has been the topic of several other reports. Stephens started coverage on shares of BioLife Solutions in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $32.00 price objective (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Finally, Zacks Research lowered shares of BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 7th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.29.

BioLife Solutions Price Performance

NASDAQ BLFS traded up $0.13 on Friday, hitting $28.79. 267,911 shares of the stock were exchanged, compared to its average volume of 462,768. The business's fifty day moving average is $26.02 and its 200 day moving average is $23.62. BioLife Solutions has a 52 week low of $19.10 and a 52 week high of $29.62. The company has a market capitalization of $1.38 billion, a PE ratio of -239.90 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The firm had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%. BioLife Solutions has set its FY 2025 guidance at EPS. Analysts predict that BioLife Solutions will post -0.3 EPS for the current fiscal year.

Insider Buying and Selling

In other BioLife Solutions news, CFO Troy Wichterman sold 1,032 shares of the firm's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $27,688.56. Following the transaction, the chief financial officer directly owned 184,186 shares of the company's stock, valued at $4,941,710.38. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the firm's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $28.55, for a total transaction of $21,412,500.00. Following the completion of the transaction, the insider directly owned 5,957,165 shares in the company, valued at approximately $170,077,060.75. This represents a 11.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,768,281 shares of company stock valued at $45,387,484. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds have recently bought and sold shares of BLFS. State of Wyoming increased its holdings in BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 1,490 shares during the period. US Bancorp DE boosted its position in BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,528 shares during the period. Ameritas Investment Partners Inc. boosted its position in BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock worth $83,000 after buying an additional 441 shares during the period. GAMMA Investing LLC lifted its position in shares of BioLife Solutions by 18.6% in the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares during the period. Finally, AlphaQuest LLC acquired a new position in shares of BioLife Solutions in the 2nd quarter worth approximately $149,000. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.